Different MOG(35-55) concentrations induce distinguishable inflammation through early regulatory response by IL-10

Alyria Teixeira Dias1, Sandra Bertelli Ribeiro De Castro2, Caio César De Souza Alves3

  • 1IMUNOCET - Department of Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, Brazil.

Cellular Immunology
|January 14, 2015
PubMed

Insights

Altering myelin oligodendrocyte glycoprotein (MOG) concentration in experimental autoimmune encephalomyelitis (EAE) models modified immune responses but did not alter disease severity. This suggests MOG levels influence EAE profiles but not chronic disease progression in multiple sclerosis (MS) models.

Area of Science:

  • Neuroimmunology
  • Autoimmune disease research
  • Animal models of neurological disorders

Background:

  • Multiple sclerosis (MS) exhibits diverse clinical presentations.
  • Experimental autoimmune encephalomyelitis (EAE) is a key animal model for MS, with varying induction protocols leading to distinct immune responses.
  • Factors driving heterogeneity in MS and EAE remain incompletely understood, particularly the role of myelin oligodendrocyte glycoprotein (MOG) concentration in regulatory responses.

Purpose of the Study:

  • To investigate whether different concentrations of MOG(35-55) (100 μg vs. 300 μg) induce distinct EAE profiles.
  • To elucidate the impact of MOG concentration on immune cell populations, cytokine/chemokine profiles, and regulatory responses in chronic EAE.

Main Methods:

  • Induction of EAE in a suitable animal model using two different concentrations of MOG(35-55) peptide.
  • Analysis of immune cell infiltration, cytokine and chemokine expression patterns, and cellular percentages within the central nervous system.
  • Assessment of the development and characteristics of regulatory immune responses.

Main Results:

  • Modifications in MOG concentration altered patterns of chemokines, cytokines, cellular composition, and inflammatory infiltrate.
  • Changes in MOG concentration influenced the development of regulatory responses.
  • Despite observed immune profile variations, neither MOG concentration significantly altered the overall intensity or chronic progression of the EAE disease course.

Conclusions:

  • MOG concentration plays a role in modulating the immune response and inflammatory profile during EAE.
  • The intensity and chronic nature of EAE progression appear independent of the specific MOG concentrations tested.
  • Findings offer insights into the complex mechanisms underlying EAE pathogenesis and the heterogeneity observed in multiple sclerosis.